Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies

被引:65
作者
Hoenigl, Martin
Raggam, Reinhard B. [2 ]
Salzer, Helmut J. F. [1 ]
Valentin, Thomas [1 ]
Valentin, Angelika [3 ]
Zollner-Schwetz, Ines [1 ]
Strohmeier, Anna T. [1 ]
Seeber, Katharina [1 ]
Woelfler, Albert [3 ]
Sill, Heinz [3 ]
Krause, Robert [1 ]
机构
[1] Med Univ Graz, Dept Internal Med, Div Pulmonol, Infect Dis Sect, A-8036 Graz, Austria
[2] Med Univ Hosp, Clin Inst Med & Chem Lab, Graz, Austria
[3] Med Univ Graz, Dept Internal Med, Div Hematol, A-8036 Graz, Austria
关键词
Posaconazole plasma concentration; Antifungal prophylaxis; Antifungal therapy; Haematological malignancy; Therapeutic drug monitoring; FUNGAL-INFECTIONS; ANTIFUNGAL PROPHYLAXIS; ASPERGILLOSIS; THERAPY; EPIDEMIOLOGY; ITRACONAZOLE; FLUCONAZOLE; EXPERIENCE; SAFETY;
D O I
10.1016/j.ijantimicag.2012.02.002
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Posaconazole (PCZ) is a triazole antifungal agent that has broad activity against pathogenic fungi and is increasingly used for prophylaxis and treatment of invasive mould infections (IMIs). PCZ is only available as an oral formulation, with varying absorption from the gastrointestinal tract. However, reports correlating PCZ plasma concentrations (PPCs) with breakthrough IMIs are rare. In this study, PPCs were analysed in a prospective, observational, single-centre study and the correlation of PPCs with breakthrough IMIs in patients with haematological malignancies was evaluated. Risk factors associated with low PPCs were further evaluated. A total of 109 PPCs were measured in 34 cases receiving PCZ prophylaxis (n = 31) or treatment (n = 3). Levels below the target of 0.5 mu g/mL were detected in 24 (71%) of the 34 cases; in 15 (63%) of these 24 cases concentrations were found to be <0.20 mu g/mL. Three patients receiving PCZ prophylaxis met the criteria of breakthrough infection. Notably, prior to development of IMI, PPCs were below the target in all three individuals. Associated risk factors for insufficient PPCs varied from previous reports. In conclusion, these data demonstrate that therapeutic drug monitoring of PCZ is mandatory in all patients with haematological malignancies as low PPCs are common and may be associated with development of IMIs. (c) 2012 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:510 / 513
页数:4
相关论文
共 28 条
[1]   Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia [J].
Al-Badriyeh, Daoud ;
Slavin, Monica ;
Liew, Danny ;
Thursky, Karin ;
Downey, Maria ;
Grigg, Andrew ;
Bajel, Ashish ;
Stewart, Kay ;
Kong, David C. M. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (05) :1052-1061
[2]   Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications [J].
Andes, David ;
Pascual, Andres ;
Marchetti, Oscar .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (01) :24-34
[3]   A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis [J].
Bryant, Alexander M. ;
Slain, Douglas ;
Cumpston, Aaron ;
Craig, Michael .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2011, 37 (03) :266-269
[4]   Posaconazole cerebrospinal concentrations in an HIV-infected patient with brain mucormycosis [J].
Calcagno, A. ;
Baietto, L. ;
De Rosa, F. G. ;
Tettoni, M. C. ;
Libanore, V. ;
Bertucci, R. ;
D'Avolio, A. ;
Di Perri, G. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (01) :224-225
[5]   Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia [J].
Cornely, Oliver A. ;
Maertens, Johan ;
Winston, Drew J. ;
Perfect, John ;
Ullmann, Andrew J. ;
Walsh, Thomas J. ;
Helfgott, David ;
Holowiecki, Jerzy ;
Stockelberg, Dick ;
Goh, Yeow-Tee ;
Petrini, Mario ;
Hardalo, Cathy ;
Suresh, Ramachandran ;
Angulo-Gonzalez, David .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (04) :348-359
[6]  
de la Cámara R, 2010, BONE MARROW TRANSPL, V45, P925, DOI 10.1038/bmt.2009.272
[7]   Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group [J].
De Pauw, Ben ;
Walsh, Thomas J. ;
Donnelly, J. Peter ;
Stevens, David A. ;
Edwards, John E. ;
Calandra, Thierry ;
Pappas, Peter G. ;
Maertens, Johan ;
Lortholary, Olivier ;
Kauffman, Carol A. ;
Denning, David W. ;
Patterson, Thomas F. ;
Maschmeyer, Georg ;
Bille, Jacques ;
Dismukes, William E. ;
Herbrecht, Raoul ;
Hope, William W. ;
Kibbler, Christopher C. ;
Kullberg, Bart Jan ;
Marr, Kieren A. ;
Munoz, Patricia ;
Odds, Frank C. ;
Perfect, John R. ;
Restrepo, Angela ;
Ruhnke, Markus ;
Segal, Brahm H. ;
Sobel, Jack D. ;
Sorrell, Tania C. ;
Viscoli, Claudio ;
Wingard, John R. ;
Zaoutis, Theoklis ;
Bennett, John E. .
CLINICAL INFECTIOUS DISEASES, 2008, 46 (12) :1813-1821
[8]   Clinical experience with posaconazole prophylaxis - a retrospective analysis in a haematological unit [J].
Hahn, J. ;
Stifel, F. ;
Reichle, A. ;
Holler, E. ;
Andreesen, R. .
MYCOSES, 2011, 54 :12-16
[9]   Epidemiology of invasive fungal infections and rationale for antifungal therapy in patients with haematological malignancies [J].
Hoenigl, M. ;
Zollner-Schwetz, I. ;
Sill, H. ;
Linkesch, W. ;
Lass-Floerl, C. ;
Schnedl, W. J. ;
Krause, R. .
MYCOSES, 2011, 54 (05) :454-459
[10]   Impact of galactomannan testing on the prevalence of invasive aspergillosis in patients with hematological malignancies [J].
Hoenigl, Martin ;
Salzer, Helmut J. F. ;
Raggam, Reinhard B. ;
Valentin, Thomas ;
Rohn, Angelika ;
Woelfler, Albert ;
Seeber, Katharina ;
Linkesch, Werner ;
Krause, Robert .
MEDICAL MYCOLOGY, 2012, 50 (03) :266-269